• 生物活性

靶点及简介 ：

Bevacizumab是一种人源化的单克隆抗体，高亲和力且特异性地与所有VEGF-A结合。贝伐单抗作为一种人源化血管内皮生长因子（VEGF）抗体，是一种高效的单克隆抗体。贝伐单抗可用于癌症研究。

Bevacizumab (anti-VEGF, Avastin) 是一种人源化的anti-VEGF单克隆抗体，是VEGF的抑制剂。可与所有人源VEGF-A亚型（和具有生物活性的蛋白水解片段）结合、中和。MW:149 KD。

体外研究 Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.

体内研究 The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.

• 验证及参考文献

验证：

参考文献：

[1] Liu W, et al. Eye Sci. Effect of Avastin on the migration and invasion of pterygium fibroblasts.

[2] Lee AL, et al. Biomacromolecules. Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of avastin with enhanced therapeutic efficiency against metastatic colorectal cancer.


关键词：Bevacizumab (anti-VEGF, Avastin)，贝伐单抗，贝伐珠单抗，bevacizumab；Avastin, Bevacizumab供应商, VEGFR/PDGFR抑制剂, 购买Bevacizumab, Bevacizumab溶解度, Bevacizumab结构式